logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12667565 B1

PDFFull Text
Date of Patent:
Jun. 30, 2026

Filed:

Nov. 26, 2020

Use of composition for enhancing anticancer effect, comprising erry inhibitor as active ingredient

Applicant:

Novmetapharma Co., Ltd., Seoul, KR;

Inventors:

Keun Gyu Park, Daegu, KR;

In Kyu Lee, Daegu, KR;

Sung Jin Cho, Daegu, KR;

Yeon Kyung Choi, Daegu, KR;

Mi Jin Kim, Daegu, KR;

Jung Wook Chin, Daegu, KR;

Yong Hyun Jeon, Daegu, KR;

Jin A Kim, Daegu, KR;

Dong Su Kim, Daegu, KR;

Hoe Yune Jung, Pohang-si, KR;

Assignee:

NOVMETAPHARMA CO., LTD., Seoul, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Clinton A Brooks

Assistant Examiner:

Nicola Maria Bauer

Int. Cl.
CPC ...
A61K 31/495 (2006.01); A61K 31/44 (2006.01); A61K 31/7105 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 15/115 (2010.01); G01N 33/575 (2026.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/495 (2013.01); A61K 31/44 (2013.01); A61K 31/7105 (2013.01); A61P 35/00 (2018.01); C07K 16/2869 (2013.01); C12N 15/115 (2013.01); G01N 33/5758 (2026.01); G01N 33/6875 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

Find Patent Forward Citations

Park, Keun. (2026). Use of composition for enhancing anticancer effect, comprising erry inhibitor as active ingredient (U.S. Patent No. 12667565). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12667565

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…